Current approaches to overcoming tumor-induced suppression of anti-tumor T cell activity depend on the use of check-point inhibitors, such as, e.g., antibodies (Abs) specific for CTLA-4, PD-1 or PD-L118, 19. Here, CTLA4 is linked to neoplasm.